It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder. Increased Aβ production plays a fundamental role in the pathogenesis of the disease and BACE1, the protease that triggers the amyloidogenic processing of APP, is a key protein and a pharmacological target in AD. Changes in neuronal activity have been linked to BACE1 expression and Aβ generation, but the underlying mechanisms are still unclear. We provide clear evidence for the role of Casein Kinase 2 in the control of activity-driven BACE1 expression in cultured primary neurons, organotypic brain slices, and murine AD models. More specifically, we demonstrate that neuronal activity promotes Casein Kinase 2 dependent phosphorylation of the translation initiation factor eIF4B and this, in turn, controls BACE1 expression and APP processing. Finally, we show that eIF4B expression and phosphorylation are increased in the brain of APPPS1 and APP-KI mice, as well as in AD patients. Overall, we provide a definition of a mechanism linking brain activity with amyloid production and deposition, opening new perspectives from the therapeutic standpoint.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Vita-Salute San Raffaele University, Milan, Italy (GRID:grid.15496.3f); IRCCS San Raffaele Scientific Institute, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
2 German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
3 Basel University Hospital, Institute of Medical Genetics and Pathology, Basel (CH), Switzerland (GRID:grid.410567.1)
4 Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan (GRID:grid.474690.8); Nagoya City University Graduate School of Medical Science, Department of Neurocognitive Science, Nagoya, Japan (GRID:grid.260433.0) (ISNI:0000 0001 0728 1069)
5 Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan (GRID:grid.474690.8)
6 BMC – Biochemistry, Ludwig Maximilians University Munich, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
7 IRCCS San Raffaele Scientific Institute, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)